Yu Qian

Yu Qian


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
WYWanlei Yang
Wanlei Yang
WHWeiqi Han
Weiqi Han
WHWei He
Wei He
JLJianlei Li
Jianlei Li
JWJirong Wang
Jirong Wang
YQYu Qian
Yu Qian

15 January 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
WYWanlei Yang
Wanlei Yang
WHWeiqi Han
Weiqi Han
AQAn Qin
An Qin
ZWZiyi Wang
Ziyi Wang
Jiake XuJiake Xu
Jiake Xu
YQYu Qian
Yu Qian

31 January 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TZTan Zhang
Tan Zhang
WHWeiqi Han
Weiqi Han
KZKangxian Zhao
Kangxian Zhao
WYWanlei Yang
Wanlei Yang
XLXuanyuan Lu
Xuanyuan Lu
YQYu Qian
Yu Qian
Bone fracture healing is a complex, dynamic process that involves various cell types, with osteoclasts and osteoblasts playing indispensable roles. In this study, we found that psoralen, the main active ingredient in Psoralea corylifolia L . fruit extract, enhanced bone fracture healing through activation of osteoclast and osteoblast activity via the ERK signaling pathway. In detail, psoralen promoted receptor activator of nuclear factor‐κB ligand‐induced osteoclastogenesis, mRNA expression of osteoclast‐specific genes, and osteoclastic bone resorption in primary bone marrow‐derived macrophages. Meanwhile, psoralen induced osteogenic differentiation by promoting the mRNA expression of the osteoblast differentiation markers alkaline phosphatase, runt‐related transcription factor 2, osterix, and osteocalcin. At the molecular level, psoralen preferentially activated ERK1/2 but not JNK or p38 MAPKs. Further experiments revealed that psoralen‐induced osteoclast and osteoblast differentiation was abrogated by a specific inhibitor of phosphorylated ERK. In addition, psoralen accelerated bone fracture healing in a rat tibial fracture model, and the numbers of osteoclasts and osteoblasts were increased in psoralen‐treated fracture callus. Taken together, our findings indicate that psoralen accelerates bone fracture healing through activation of osteoclasts and osteoblasts via ERK signaling and has potential as a novel drug in the orthopedic clinic for the treatment of bone fractures.—Zhang, T., Han, W., Zhao, K., Yang, W., Lu, X., Jia, Y., Qin, A., Qian, Y. Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts. FASEB J. 33, 5399–5410 (2019). www.fasebj.org

12 July 2021 in Bone Research
Verified
Journal Article
Open access
PDF file
WYWanlei Yang
Wanlei Yang
XLXuanyuan Lu
Xuanyuan Lu
TZTan Zhang
Tan Zhang
WHWeiqi Han
Weiqi Han
JLJianlei Li
Jianlei Li
YQYu Qian
Yu Qian
Osteoporosis is an osteolytic disorder commonly associated with excessive osteoclast formation. Transcriptional coactivator with PDZ-binding motif (TAZ) is a key downstream effector of the Hippo signaling pathway; it was suggested to be involved in the regulation of bone homeostasis. However, the exact role of TAZ in osteoclasts has not yet been established. In this study, we demonstrated that global knockout and osteoclast-specific knockout of TAZ led to a low-bone mass phenotype due to elevated osteoclast formation, which was further evidenced by in vitro osteoclast formation assays. Moreover, the overexpression of TAZ inhibited RANKL-induced osteoclast formation, whereas silencing of TAZ reduced it. Mechanistically, TAZ bound to TGF-activated kinase 1 (TAK1) and reciprocally inhibited NF-κB signaling, suppressing osteoclast differentiation. Collectively, our findings highlight an essential role of TAZ in the regulation of osteoclastogenesis in osteoporosis and its underlying mechanism.

1 March 2020 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YJYewei Jia
Yewei Jia
WHWei He
Wei He
HZHanxiao Zhang
Hanxiao Zhang
LHLei He
Lei He
YWYanben Wang
Yanben Wang
YQYu Qian
Yu Qian
Purpose: Osteoarthritis (OA) is one of the most common degenerative joint diseases in the world, characterized primarily by the progressive degradation of articular cartilage. Accumulating evidence has shown that Morusin, a flavonoid derived from the root bark of Morus alba (mulberry) plants, exerts unique protective properties in several diseases. However, its effects on OA, specifically, have not yet been characterized. Methods: In this study, we evaluated the anti-inflammatory effect of Morusin on mouse chondrocytes and its underlying mechanism in vitro. In addition, the protective effect of Morusin on destabilization of the medial meniscus (DMM) model was also explored in vivo. Results: In vitro, IL-1β-induced activation of inflammatory factors (TNF-α, IL-6, INOS and COX2) was dramatically suppressed by Morusin. Further, Morusin treatment inhibited the expression of ADAMTS5 and metalloproteinase (MMPs), both of which regulate extracellular matrix degradation. Morusin also decreased IL-1β-induced p65 phosphorylation and IκBα degradation. In vivo, degradation of the articular cartilage following surgical DMM, which mimicked OA pathology, was abrogated following treatment with Morusin, thus demonstrating a protective effect in the DMM model. Conclusion: Herein, we demonstrate that Morusin reduces the OA inflammatory response in vitro and protects against articular cartilage degradation in vivo potentially via regulation of the NF-κB pathway. Hence, Morusin may prove to be an effective candidate for novel OA therapeutic strategies.

15 June 2019 in Inflammation
Verified
Journal Article
Closed access
PDF file
YJYewei Jia
Yewei Jia
CPCong Pang
Cong Pang
KZKangxian Zhao
Kangxian Zhao
JJJiawei Jiang
Jiawei Jiang
TZTan Zhang
Tan Zhang
YQYu Qian
Yu Qian